This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bovie Medical Corporation Comments On Recent Corporate Activities

Bovie Medical Corporation (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today commented on recent corporate activities.

Vessel Sealing Products

The Federal District Court Complaint, filed in Tampa, Florida against Steve Livneh, Lican Development, Ltd. and Henvil Corp. (both controlled by Mr. Livneh), was instituted to protect the Company and its shareholders from ongoing actions by the defendants that were considered damaging to Bovie’s best interests. Mr. Livneh was removed from the Board for cause at a Special Board Meeting held on July 16, 2010. Despite these unwelcome diversions, the Company proceeds with its vessel sealing product research and testing protocols necessary for the FDA 510K submission process. Developmental and engineering progress continues to be made while vice president of sales and marketing for surgical products, Jeff Rencher, prepares to market the Company’s vessel sealing products and other offerings.

Recent J-Plasma Developments

The Company is actively developing enhancements to its J-Plasma™ product, which leverage and combine unique properties of J-Plasma™ ionized helium gas together with surgical instrumentation under development. The enhancements are expected to have potential application to a broad variety of surgical procedures. The Company is coordinating with a number of leading university surgeons who will evaluate the J-Plasma™ enhancements in diverse surgical specialties. The Company is planning to file new patents related to these potential uses and intends to display its J-Plasma™ as well as other products at the 39 th AAGL Global Congress of Minimally Invasive Gynecology in Las Vegas November 8-12, 2010.

Sintered Steel

The Company continues to advance its Sintered Steel product lines, and while temporarily delayed by the Salient/Medtronic litigation, is moving forward with its SEER™ and BOSS™ marketing.

In Other News

Mr. Rencher, as part of market planning for all of Bovie’s specialty surgical products, foresees the addition of up to 100 independent sales representatives located throughout the United States during the next twelve months. Shipments of surgical products, including the recently released Bovie coated electrodes, will commence by month’s end to the new specialty sales reps. The Company also reports the extension of its OEM agreement with Medtronic Inc. through 2012.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
BVX $3.19 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs